Facebook
X
LinkedIn
ForwardAwareness of Emerging Therapeutic Landscape
Program Overview
The Interstitial Lung Disease Education Center (ILDEC), was developed by the ATS in collaboration with leading subject matter experts, highlights the rapidly evolving therapeutic landscape for ILDs. This brief activity examines emerging treatment options, detailing their mechanisms of action and the potential impact these therapies may have on disease progression and patient outcomes. This module equips clinicians and care teams with practical insights to better evaluate new ILD therapies and integrate evidence-based advances into patient care.
Target Audience
The target audience for this educational initiative is pulmonologists, radiologists, and general practitioners who encounter patients with interstitial lung disease.
Learning Objectives
Upon completion of this course, the learners should be able to:
- Evaluate emerging therapies for ILDs, including their mechanisms of action and potential impact on disease progression and patient outcomes
Copyright Information
Copyright © 2025 American Thoracic Society. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without written permission from American Thoracic Society.
Commercial Support Acknowledgment
Funding for this project was provided by Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. did not have input on content development.
Faculty
Joyce S. Lee, MD, MAS, ATSF
Professor of Medicine
Director, Interstitial Lung Disease Program
University of Colorado - Anschutz Medical Campus
Aurora, CO
Disclosures
Non-CE consulting : AstraZeneca, Blade, Boehringer Ingelheim, Elima, Eleven P15, Foresee, Pliant, United Therapeutics, Gatehouse Bio, Mannkind, Mediar Therapeutics, Pulmonary Fibrosis Foundation, Avalyn, GlaxoSmithKline, and Syndax.
Advisory Board: Boehringer Ingelheim
Grant/contract: Boehringer Ingelheim, Bristol-Myers Squibb, National Heart, Lung, and Blood Institute, and Tvardi
Toby M. Maher, MD, PhD
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
University of Southern California
Director of Interstitial Lung Disease
Division of Pulmonary, Critical Care, and Sleep Medicine
Keck Medicine of USC
Disclosures
Non-CE consulting : Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech USA, Inc., GlaxoSmithKline, Merck & Co., Inc., PureTech Health, Sanofi Pasteur Inc., Trevi Therapeutics, FibroGen, and United Therapeutics
Planning Committee
Joyce S. Lee, MD, MAS, ATSF
Professor of Medicine
Director, Interstitial Lung Disease Program
University of Colorado - Anschutz Medical Campus
Aurora, CO
Disclosures
Non-CE consulting : AstraZeneca, Blade, Boehringer Ingelheim, Elima, Eleven P15, Foresee, Pliant, United Therapeutics, Gatehouse Bio, Mannkind, Mediar Therapeutics, Pulmonary Fibrosis Foundation, Avalyn, GlaxoSmithKline, and Syndax.
Advisory Board: Boehringer Ingelheim
Grant/contract: Boehringer Ingelheim, Bristol-Myers Squibb, National Heart, Lung, and Blood Institute, and Tvardi
Deji Adegunsoye, MD, MSc, PhD, FCCP
Assistant Professor of Medicine
Scientific Director, Interstitial Lung Disease Program
University of Chicago Medicine
Chicago, IL
Disclosures
Non-CE consulting: Abbvie, Baxter Healthcare, Boehringer Ingelheim, and Puretech Health
Grant/contract: National Heart, Lung, and Blood Institute and Roche
Speaker: Boehringer Ingelheim
Justin Oldham, MD PhD
Associate Professor
Director, ILD Research
University of Michigan
Ann Arbor, MI
Disclosures
Non-CE consulting: Boehringer Ingelheim, Gatehouse Bio, Lupin Pharmaceuticals, Genentech, and Novartis
Grant/contract: National Heart, Lung, and Blood Institute
Toby M. Maher, MD, PhD
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
University of Southern California
Director of Interstitial Lung Disease
Division of Pulmonary, Critical Care, and Sleep Medicine
Keck Medicine of USC
Disclosures
Non-CE consulting : Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech USA, Inc., GlaxoSmithKline, Merck & Co., Inc., PureTech Health, Sanofi Pasteur Inc., Trevi Therapeutics, FibroGen, and United Therapeutics
Melissa Glasner
Manager, Medical Content
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Amanda Noe
Senior Manager, Medical Education and Client Services
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Erika Fox
Senior Project Manager
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Jennifer Siegel-Gasiewski, MPA
Director of Lifelong Learning
American Thoracic Society
New York, NY
Disclosures
Nothing to disclose
Content Reviewer
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
Disclosures:
Nothing to disclose
It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. For non-accredited continuing education, planners, faculty, reviewers, and activity staff are required to disclose any financial relationships they have with commercial entities including specific disclosure of relationships with companies and organizations associated with tobacco or cannabis or those designated as ineligible companies by the ACCME. The ATS prohibits or limits participation of faculty in official ATS activities if any tobacco industry relationship or some types of cannabis industry relationships is present. The most recent policies regarding potential conflicts of interest as well as the mechanisms to mitigate or resolve such conflicts can be found here: COI Policy for Official ATS Activities (thoracic.org): COI Policy for Official ATS Activities (thoracic.org)
All relevant financial relationships listed have been mitigated
Required Hardware/software
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers.
Additionally, this site and its activities are best viewed using the latest Operating System for your device.